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A B S T R A C T
A novel approach for brain protection against poisoning by organophosphorus agents is developed based on the
combination treatment of dual delivery of two oximes. Pralidoxime chloride (2-PAM) and a novel reactivator, 6-
(5-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)pentyl)-3-hydroxy picolinaldehyde oxime (3-HPA), have
been loaded in solid-lipid nanoparticles (SLNs) to oﬀer distinct release proﬁle and systemic half-life for both
oximes. To increase the therapeutic time window of both oximes, SLNs with two diﬀerent compartments were
designed to load each respective drug. Oxime-loaded SLNs of hydrodynamic diameter between 100 and 160 nm
and negative zeta potential (−30 to −25mV) were stable for a period of 10months at 4 °C. SLNs displayed
longer circulation time in the bloodstream compared to free 3-HPA and free 2-PAM. Oxime-loaded SLNs were
suitable for intravenous (iv) administration. Paraoxon-poisoned rats (0.8× LD50) were treated with 3-HPA-
loaded SLNs and 2-PAM+3-HPA-loaded SLNs at the dose of 3-HPA and 2-PAM of 5mg/kg. Brain AChE re-
activation up to 30% was slowly achieved in 5 h after administration of 3-HPA-SLNs. For combination therapy
with two oximes, a time-dependent additivity and increased reactivation up to 35% were observed.
1. Introduction
Multidrug combination therapy is one of the promising approaches
for treatment of chronic diseases. Nanotechnological “two-in-one” ap-
proach using nanoparticles for packaging multiple drugs in single car-
riers allows the improvement of drugs' bioavailability, with the si-
multaneous decrease of administered doses and adverse side-reactions
[1–4]. Nanoparticles exhibit targeted delivery of drugs and modiﬁed
release proﬁle and, when loaded with two drugs, may foster synergistic
therapeutic outcomes [2]. To date, prevention of irreversible brain
damages after acute organophosphorus (OP) poisoning is still a diﬃcult
problem, in particular in case of delayed medical care [5]. OP threat has
become increasingly important due to acts of terrorism around the
globe that have increased markedly in recent decades, and due to the
proved use of these agents against civilian populations in Iraq and
Syria. The acute toxicity of OPs results from covalent inhibition,
phosphylation, of acetylcholinesterase (AChE). Low OP doses do not
induce clinical manifestations of cholinergic impairment. It is accepted
that clinical signs of poisoning appear when cholinesterase activity
drops below 50% [6]. Severe signs, in particular convulsions, appear
when AChE activity of poisoned patients is below 10–20% [7]. In hu-
mans, brain AChE activity< 10% is associated with respiratory failure
and death [8]. Thus, the current emergency treatment of acute OP
poisoning consists in administering a combination of AChE reactivator
(quaternary oximes), atropine as anticholinergic drug to protect mus-
carinic receptors, and an anticonvulsant to prevent irreversible brain
damage [5,9]. However, current quaternary oximes are unable to re-
activate phosphylated AChE in the central nervous system (CNS)
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